Literature DB >> 8625109

Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma.

W H Morrison1, R M Byers, A S Garden, H L Evans, K K Ang, L J Peters.   

Abstract

BACKGROUND: Because of a tendency for diffuse, clinically undetectable local spread, cutaneous angiosarcoma is difficult to treat with surgery alone. Radiation is a rational treatment modality for this disease, because a wide region of dermis can be treated, whereas the underlying normal tissues are spared.
METHODS: The authors retrospectively studied 14 patients with dermal angiosarcoma of the head and neck who were treated with electron-beam radiation from 1970 to 1989. Primary tumors were located in the scalp and forehead (11 patients) and in the upper face (3 patients). Eleven patients presented with multiple foci of disease. Three patients were treated with radiotherapy alone; the other 11 were treated with chemotherapy (10 patients) and/or surgery (7 patients). Surgical excisions were limited procedures for patients whose disease readily could be encompassed; total scalp resections were not performed. Patients were irradiated with a multiple-field electron-beam technique. Six patients presented postoperatively for radiotherapy with no macroscopic disease in the treatment field and were given a median dose of 60 Gy (range, 50-66 Gy) over a median of 40 days (range, 37-43 days). Eight patients were irradiated with clinically evident disease; doses ranged from 55 to 75 Gy over a median of 44 days (range, 33-66 days).
RESULTS: Five of the six patients irradiated without clinically detectable disease were controlled in the treatment field, but only two are currently disease free. Of the eight patients irradiated with macroscopic tumor, initial disease recurrence occurred in the radiation field in two patients and at the radiation field margin in three patients. The actuarial 5-year control rates above the clavicles for patients irradiated with and without clinical disease were 24% and 40%, respectively (P = 0.03). The 5-year actuarial incidence of distant metastases for all patients was 63%. The 5-year actuarial survival rate for patients irradiated with and without clinical disease was 13% and 50%, respectively (P = .04).
CONCLUSIONS: Radiation is an effective modality for treating local disease, especially when used after surgical resection of macroscopic tumor. Our current strategy is to resect clinically evident tumor in patients presenting with focal, limited disease, and to follow this resection with moderate dose, very wide-field radiation. The survival outcome for patients presenting with diffuse multifocal disease is bleak, but some patients can be controlled infield with radiation. There must be continued efforts to develop effective systemic therapy.

Entities:  

Mesh:

Year:  1995        PMID: 8625109     DOI: 10.1002/1097-0142(19950715)76:2<319::aid-cncr2820760224>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

1.  Cutaneous angiosarcoma of the eyelids.

Authors:  R M Conway; T Hammer; A Viestenz; L M Holbach; R M Conway
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

2.  The importance of surgery in scalp angiosarcomas.

Authors:  Richard J Cassidy; Jeffrey M Switchenko; Melinda L Yushak; Nicholas Madden; Mohammad K Khan; David K Monson; Jonathan J Beitler; Jerome C Landry; Karen D Godette; Theresa W Gillespie; Kirtesh R Patel
Journal:  Surg Oncol       Date:  2018-09-13       Impact factor: 3.279

3.  Cutaneous angiosarcoma: a single-institution experience.

Authors:  Matthew C Perez; Tapan A Padhya; Jane L Messina; Ryan S Jackson; Ricardo J Gonzalez; Marilyn M Bui; G Douglas Letson; C W Cruse; Robert S Lavey; David Cheong; Meghan R Forster; William J Fulp; Vernon K Sondak; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2013-07-09       Impact factor: 5.344

Review 4.  Current and Future Directions for Angiosarcoma Therapy.

Authors:  Vaia Florou; Breelyn A Wilky
Journal:  Curr Treat Options Oncol       Date:  2018-03-08

5.  Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp.

Authors:  B Ashleigh Guadagnolo; Gunar K Zagars; Dejka Araujo; Vinod Ravi; Thomas D Shellenberger; Erich M Sturgis
Journal:  Head Neck       Date:  2010-10-19       Impact factor: 3.147

6.  Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment.

Authors:  Jong-Hyuk Kim; Aric M Frantz; Katie L Anderson; Ashley J Graef; Milcah C Scott; Sally Robinson; Leslie C Sharkey; Timothy D O Brien; Erin B Dickerson; Jaime F Modiano
Journal:  Exp Cell Res       Date:  2014-02-25       Impact factor: 3.905

Review 7.  Sarcomas of the head and neck region.

Authors:  Thomas D Shellenberger; Erich M Sturgis
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

8.  Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model.

Authors:  Nasim Akhtar; Marcia L Padilla; Erin B Dickerson; Howard Steinberg; Matthew Breen; Robert Auerbach; Stuart C Helfand
Journal:  Neoplasia       Date:  2004 Mar-Apr       Impact factor: 5.715

Review 9.  Management of angiosarcoma.

Authors:  G Thomas Budd
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

10.  Angiosarcoma of the scalp.

Authors:  Manjiri Das Gupta; Nilay Chakrabarti; Pravin Agrawal; Swati Narurkar
Journal:  Indian J Plast Surg       Date:  2009 Jan-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.